UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000035462 |
|---|---|
| Receipt number | R000040401 |
| Scientific Title | Pancreatic cancer project in Matsue |
| Date of disclosure of the study information | 2019/01/06 |
| Last modified on | 2019/01/06 17:55:39 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Pancreatic cancer project in Matsue
Acronym
Pancreatic cancer project in Matsue
Scientific Title
Pancreatic cancer project in Matsue
Scientific Title:Acronym
Pancreatic cancer project in Matsue
Region
| Japan |
Condition
Condition
Pancreatic tumor
Classification by specialty
| Hepato-biliary-pancreatic medicine | Adult |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
We verify the detecting rate of pancreatic cancer by collaboration between general practitioners and general hospitals.
Basic objectives2
Others
Basic objectives -Others
a prospective observational study
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Detecting rate of pancreatic cancer
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| 120 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Patients with suspected pancreatic cancer from clinical symptoms
Patients with multiple pancreatic cancer risk factors
Patients that pancreatic cancer can not be denied from the clinical course
Key exclusion criteria
none
Target sample size
300
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kazuya Matsumoto |
Organization
Medical corporation
Irisawa Medical Clinic
Division name
Internal Medicine
Zip code
Address
285-6, Yawata-cho, Matsue 690-0025
TEL
0852-38-8211
matsumotokazuya@med.tottori-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Kazuya Matsumoto |
Organization
Medical corporation Irisawa Medical Clinic
Division name
Internal Medicine
Zip code
Address
285-6, Yawata-cho, Matsue 690-0025
TEL
0852-38-8211
Homepage URL
matsumotokazuya@med.tottori-u.ac.jp
Sponsor or person
Institute
Matsue Medical Association
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 01 | Month | 06 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2018 | Year | 04 | Month | 21 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 06 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
When abdominal ultrasound show main pancreatic ductal dilation, pancreatic cyst, and pancreatic tumor lesion, abnormality is found in blood test, or if pancreatic cancer can not be denied from the clinical course, We perform further examinations at general hospital. The case in which further examinations was performed is registered in the "Matsue pancreatic cancer project".
Management information
Registered date
| 2019 | Year | 01 | Month | 06 | Day |
Last modified on
| 2019 | Year | 01 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040401
